Research brief: Female fracture risk reduced

Five years of bisphosphonate therapy may be sufficient to increase bone mineral density (BMD) and reduce the risk of fracture in women, say US researchers. The study involved 1,099 postmenopausal women with low BMD who had taken alendronate for five or 10 years before withdrawal. Women who discontinued alendronate after five years showed a moderate decline in BMD but no higher fracture risk then those who continued alendronate (JAMA 2006; 296: 2,927–38).

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in